8,234 Shares in Lantheus Holdings, Inc. $LNTH Acquired by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 2nd quarter, Holdings Channel.com reports. The firm bought 8,234 shares of the medical equipment provider’s stock, valued at approximately $913,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Farallon Capital Management LLC raised its holdings in Lantheus by 56.1% during the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after purchasing an additional 1,950,252 shares during the last quarter. Jupiter Topco LLC bought a new stake in shares of Lantheus in the 2nd quarter valued at $575,628,000. Reinhart Partners LLC. boosted its stake in shares of Lantheus by 2.2% in the 2nd quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock valued at $177,437,000 after purchasing an additional 34,501 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Lantheus by 3.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider’s stock worth $94,202,000 after buying an additional 44,374 shares during the period. Finally, Carmignac Gestion increased its position in shares of Lantheus by 18.4% during the first quarter. Carmignac Gestion now owns 1,328,000 shares of the medical equipment provider’s stock worth $100,729,000 after buying an additional 206,000 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. B. Riley Financial lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Monday, August 17th. Wall Street Zen downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Truist Financial downgraded Lantheus from a “buy” rating to a “hold” rating and decreased their price target for the stock from $125.00 to $102.50 in a report on Monday, August 3rd. Mizuho lowered their price objective on Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Wednesday, July 29th. Finally, Brookline Capital Markets downgraded Lantheus from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Four investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $108.11.

Lantheus Stock Performance

Shares of LNTH stock opened at $100.77 on Monday. The firm has a 50 day moving average of $103.74 and a 200-day moving average of $91.76. The company has a market cap of $6.58 billion, a price-to-earnings ratio of 24.34 and a beta of -0.03. The company has a quick ratio of 2.89, a current ratio of 3.06 and a debt-to-equity ratio of 0.43. Lantheus Holdings, Inc. has a 52 week low of $49.67 and a 52 week high of $111.86.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. The company had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. Lantheus’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.57 EPS. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 4.48 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.